Citi analyst Geoff Meacham raised the firm’s price target on Royalty Pharma (RPRX) to $66 from $50 and keeps a Buy rating on the shares. The firm views the company’s Q1 report as strong.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma’s Earnings Call Signals Confident Growth
- Royalty Pharma price target raised to $57 from $51 at UBS
- Royalty Pharma: Leveraged Biopharma Catalysts and De-Risked Royalty Growth Support Further Upside
- Royalty Pharma Expands Daraxonrasib Royalty Stake After Milestone
- Royalty Pharma price target raised to $63 from $61 at Morgan Stanley